Pfizer ends phase 2 trial for lymphoma drug from Trillium acquisition

6 days ago 3
Pfizer HQ in New York City

georgeclerk

  • Citing recruitment problems, Pfizer has ended a phase 2 trial of maplirpacept, a candidate targeting CD47 that the drug giant obtained in August 2021 as part of its $2.26B acquisition of Trillium Therapeutics.
  • "The trial terminated due to the inability

Recommended For You

More Trending News

Read Entire Article